Brain Metastases from Ovarian Carcinoma

Table 1

Incidence of CNS metastases among ovarian carcinoma patients, interval between diagnosis of ovarian carcinoma and CNS metastases, survival after diagnosis of ovarian carcinoma, and survival after diagnosis of CNS metastases.

Author (year) [ref.]	Study period	Number of patients with OC	Number of patients with CNS metastases (%)	Median Interval between diagnosis of OC and CNS metastases in months (range)	Median survival after diagnosis of OC in months (range)	Median survival after diagnosis of CNS metastases in months (range)
Mayer et al. (1978) [13]	1973–1977	NA	6	26 (2–82)	38 (8–85+)	4.5 (2–33+)
Barker et al. (1981) [24]	1969–1979	430	4 (0.9)	34 (11–72)	37 (13–78)	4 (0.2–8)
Budd et al. (1983) [25]	1978–1980	42	3 (7.1)	19 (19–20)	NA	NA
Larson et al. (1986) [20]	1944–1984	4,456	13 (0.29)	NA	26	5
Stein et al. (1986) [26]	1979–1985	110	5 (4.5)	17 (16–43)	28 (18–43)	2 (1–11)
Dauplat et al. (1987) [27]	1973–1983	255	5 (1.96)	25 (10–126)	24 (11–135)	1 (1–10)
Ziegler et al. (1987) [28]	1983–1985	NA	5	11 (11–31)	NA	8 (1–9+)
Ross et al. (1988) [29]	1980–1984	342	7 (2)	NA	27 (12–52)	6.5 (2–26)
Hardy and Harvey (1989) [30]	1981–1984	52	6 (11.6)	28.5 (0–36)	30 (3–126)	4.5 (2–41+)
Piura et al. (1990) [31]	1961–1988	200	2 (1)	22 (21–23)	41.5 (40–43)	19.5 (19–20)
Plaxe et al. (1990) [32]	NA	NA	6	28.5 (2–61)	NA	10 (2–24)
LeRoux et al. (1991) [33]	1980–1989	1,316	14 (1.1)	14.5 (0–72)	NA	3 (0.1–36)
Rodriguez et al. (1992) [34]	1977–1990	795	16 (2)	NA	NA	9
Bruzzone et al. (1993) [35]	1981–1989	413	9 (2.2)	19 (3–36)	26 (10–81)	8 (1–45)
Salvati and Cervani (1994) [36]	1980–1988	NA	4	21 (10–26)	NA	28 (17–48)
Geisler and Geisler (1995) [37]	1979–1992	479	16 (3.3)	19 (2–41)	NA	3 (1–24)
Cormio et al. (1995) [38]	1982–1994	NA	23	35 (5–114)	42 (8–133)	5 (1–24)
Suzuki et al. (1999) [39]	1982–1998	311	4 (1.3)	NA	NA	NA
Zhao et al. (1999) [40]	1989–1997	132	4 (3%)	NA	NA	10 (2–19+)
Kaminsky-Forrett et al. (2000) [41]	1974–1998	704	8 (1.1)	15 (2–80)	NA	3 (1–12)
Sanderson et al. (2002) [42]	1995–2000	1,222	13 (1.1)	36 (6–60)	NA	6 (2–42+)
Anupol et al. (2002) [43]	1986–2000	1,042	15 (1.4)	22 (0–53)	38 (9–82)	6 (0–49)
Kolomainen et al. (2002) [21]	1980–2000	3,690	18 (0.5)	46 (12–113)	NA	7 (1–41)
Pothuri et al. (2002) [44]	1989–2001	NA	14	42 (15.6–98.4)	NA	18 (0.5–32.8)
Kumar et al. (2003) [45]	1991–2001	658	18 (2.7)	29 (0–101)	30.5 (5–110)	4 (1–74)
Li and Fu (2003) [46]	1996–2000	478	10 (2.1)	NA	NA	6.3 (<1–33)
Cohen et al. (2004) [47]	1975–2001	8,225	72 (0.9)	22 (0–219)	40.5 (95% CI, 21.5–60)	6.3 (95% CI, 5–8)
Tay and Rajesh (2005) [48]	1993–2003	605	4 (0.66)	16.5 (8–65)	NA	19.5
Pectasides et al. (2005) [49]	1983–2004	1,450	17 (1.17)	15.9 (1.4–70.8)	27.4 (3–71.4)	5.7 (0.2–22.6)
D’Andrea et al. (2005) [50]	1980–2000	NA	11	21	NA	28
Chen et al. (2005) [51]	1985–2002	NA	19	25.2 (−0.6–112)	NA	16.3 (0.2–111.5)
Kastritis et al. (2006) [52]	1995–2004	267	8 (3)	17.2	67 (95% CI, 48–85)	22 (95% CI, 12–34)
Kim et al. (2007) [53]	1996–2005	490	13 (2.7)	28 (13–99)	NA	7 (0–30)
Ogawa et al. (2008) [6]	1985–2006	335	7 (2.1)	NA	NA	7.3 (0.9–48.2)
Lee et al. (2008) [54]	1983–2005	1,413	18 (1.3)	28 (8–71)	NA	14 (1–63)
Sehouli et al. (2010) [55]	1981–2008	4,277	74 (1.7)	28.8 (2.6–133.1)	36.2 (95% CI, 33.3–39.1)	6.2 (95% CI, 4.9–7.5)
Chen et al. (2011) [22]	2000–2007	539	10 (1.9)	24.3 (7–55)	NA	3 (0–16)
Cormio et al. (2011) [56]	1995–2010	NA	20	33 (3–70)	NA	17.6 (0–59)
Total		34,728^a	521^b 413^c (1.19)	24.3 (11–46)^d	33.3 (24–67)^d	6.4 (1–28)^d

CNS: central nervous system; OC: ovarian carcinoma; NA: not available.
^aThis number represents the total number of patients with ovarian carcinoma in 29 series in which the number of ovarian carcinoma patients is available.
^bThis number represents the total number of patients with brain metastases from ovarian carcinoma in all 38 series reviewed.
^cThis number represents the total number (percentage) of patients with brain metastases from ovarian carcinoma in 29 series in which the number of ovarian carcinoma patients is available.
^dMedian (range) of the medians. Interval between diagnosis of ovarian carcinoma and brain metastases was available in 31 series totaling 460 patients. Survival after diagnosis of ovarian carcinoma was available in 16 series totaling 236 patients. Survival after diagnosis of brain metastases was available in 36 series totaling 513 patients.